KRYSTAL BIOTECH INC (KRYS) Stock News

USA - NASDAQ:KRYS - US5011471027 - Common Stock

190.78 USD

-5.18 (-2.64%)

Last: 10/21/2025, 8:00:02 PM

190.78 USD

0 (0%)

After Hours: 10/21/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KRYS Latest News, Press Relases and Analysis

All

Press Releases

22 hours ago - By: Krystal Biotech, Inc.

Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

5 days ago - By: Benzinga

Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts

6 days ago - By: Benzinga

$100 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today

8 days ago - By: Krystal Biotech, Inc.

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

22 days ago - By: Zacks Investment Research - Mentions: BMY MRK

Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?

a month ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

2 months ago - By: Zacks Investment Research - Mentions: ALKS

Krystal Biotech (KRYS) Up 8.5% Since Last Earnings Report: Can It Continue?

3 months ago - By: The Motley Fool

Krystal (KRYS) Q2 Profit Jumps 143%

2 months ago - By: Krystal Biotech, Inc.

Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

2 months ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

3 months ago - By: Yahoo Finance

Krystal Biotech price target lowered to $182 from $192 at BofA

3 months ago - By: Zacks Investment Research - Mentions: CRMD IMCR

KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook

3 months ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

3 months ago - By: Zacks Investment Research - Mentions: TNGX

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

3 months ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa

3 months ago - By: Krystal Biotech, Inc.

Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté

3 months ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis

4 months ago - By: The Motley Fool - Mentions: TMDX PODD OPCH BEAM ...

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

4 months ago - By: Krystal Biotech, Inc.

Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa